Survival Analysis in a Colombian Cohort of Mantle Cell Lymphoma. A Real-World Experience

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2025-04-22 DOI:10.1002/hon.70085

Juan F. Combariza-Vallejo, Rocío Orduz-Rodriguez, Natalia Gomez-Lopera, Claudia C. Colmenares-Mejia, Fabián A. Mejía-Casadiego, Marcela Godoy-Corredor, Mario Arturo Isaza-Ruget

{"title":"Survival Analysis in a Colombian Cohort of Mantle Cell Lymphoma. A Real-World Experience","authors":"Juan F. Combariza-Vallejo, Rocío Orduz-Rodriguez, Natalia Gomez-Lopera, Claudia C. Colmenares-Mejia, Fabián A. Mejía-Casadiego, Marcela Godoy-Corredor, Mario Arturo Isaza-Ruget","doi":"10.1002/hon.70085","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Mantle cell lymphoma is a type of B-cell lymphoma with limited epidemiologic data in Latin America. The main objective was evaluating survival, in mantle cell lymphoma in Colombia and the influence of hematopoietic stem cell transplantation in the outcomes. In a retrospective cohort of new diagnostic Mantle Cell Lymphoma between 2010 and 2024, we identified main characteristics at diagnosis and the influence of MIPI score and ASCT. We followed patients until progression or death and compared progression-free survival and overall survival. We included 139 patients; the median age was 64 years. For patients classified as low risk according to the MIPI score, the 36-month OS rate was 79.7% (95% CI: 68%–93.5%). Intermediate risk 51.5% (95% CI: 38.2%–69.4%). And High-risk 40.4% (95% CI: 26.9%–59.5%) (<i>p</i> < 0.001). In the group that underwent ASCT, the 36-month OS rate was 75.2% (95% CI: 60.1%–94.6%), and in the non-transplanted group was 49% (95% CI: 39.5%–60.7%), HR 0.38 (95% CI; 019–0.74) (<i>p</i> = 0.002). High-risk patients and those who were not transplanted had the lowest survival compared to the other categories. These findings underscore the need for risk stratification, and effective treatment strategies, including the HSCT patient population in Colombia.</p>\n </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 3","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70085","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Mantle cell lymphoma is a type of B-cell lymphoma with limited epidemiologic data in Latin America. The main objective was evaluating survival, in mantle cell lymphoma in Colombia and the influence of hematopoietic stem cell transplantation in the outcomes. In a retrospective cohort of new diagnostic Mantle Cell Lymphoma between 2010 and 2024, we identified main characteristics at diagnosis and the influence of MIPI score and ASCT. We followed patients until progression or death and compared progression-free survival and overall survival. We included 139 patients; the median age was 64 years. For patients classified as low risk according to the MIPI score, the 36-month OS rate was 79.7% (95% CI: 68%–93.5%). Intermediate risk 51.5% (95% CI: 38.2%–69.4%). And High-risk 40.4% (95% CI: 26.9%–59.5%) (p < 0.001). In the group that underwent ASCT, the 36-month OS rate was 75.2% (95% CI: 60.1%–94.6%), and in the non-transplanted group was 49% (95% CI: 39.5%–60.7%), HR 0.38 (95% CI; 019–0.74) (p = 0.002). High-risk patients and those who were not transplanted had the lowest survival compared to the other categories. These findings underscore the need for risk stratification, and effective treatment strategies, including the HSCT patient population in Colombia.

查看原文本刊更多论文

哥伦比亚套细胞淋巴瘤队列的生存分析。真实世界的经验

套细胞淋巴瘤是一种b细胞淋巴瘤，在拉丁美洲流行病学资料有限。主要目的是评估哥伦比亚套细胞淋巴瘤患者的生存率以及造血干细胞移植对预后的影响。在2010年至2024年间新诊断套细胞淋巴瘤的回顾性队列中，我们确定了诊断时的主要特征以及MIPI评分和ASCT的影响。我们跟踪患者直到进展或死亡，并比较无进展生存期和总生存期。我们纳入了139例患者；中位年龄为64岁。根据MIPI评分划分为低风险的患者，36个月的OS率为79.7% （95% CI: 68%-93.5%）。中间风险为51.5% （95% CI: 38.2%-69.4%）。和高风险40.4% (95% CI: 26.9% - -59.5%) (p & lt;0.001)。在接受ASCT的组中，36个月的OS率为75.2% (95% CI: 60.1%-94.6%)，未移植组为49% (95% CI: 39.5%-60.7%), HR 0.38 (95% CI；019-0.74) （p = 0.002）。与其他类别相比，高危患者和未接受移植的患者生存率最低。这些发现强调了风险分层和有效治疗策略的必要性，包括哥伦比亚的HSCT患者群体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.